GlaxoSmithKline: European Commission Authorizes Nimenix
04/27/2012| 08:24am US/Eastern
GlaxoSmithKline PLC (>> GlaxoSmithKline plc), the drug company, said Friday that the European Commission has granted marketing authorization for Nimenrix, Meningococcal group A, C, W-135 and Y conjugate vaccine, for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.
-Shares at 1207 GMT, up a penny, or 0.04%, at 1,420.5 pence valuing the company at GBP71.61 billion.
-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; email@example.com